Nuvalent Inc (NUVL)vsVertex Pharmaceuticals Inc (VRTX)
NUVL
Nuvalent Inc
$90.95
-3.27%
HEALTHCARE · Cap: $9.75B
VRTX
Vertex Pharmaceuticals Inc
$466.79
+1.45%
HEALTHCARE · Cap: $114.33B
Smart Verdict
WallStSmart Research — data-driven comparison
VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
NUVL
Avoid25
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NUVL.
Margin of Safety
+52.4%
Fair Value
$949.55
Current Price
$466.79
$482.76 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NUVL
The strongest argument for NUVL centers on Altman Z-Score.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : NUVL
The primary concerns for NUVL are Revenue Growth, EPS Growth, Profit Margin.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
NUVL profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
NUVL carries more volatility with a beta of 1.15 — expect wider price swings.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 25/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Nuvalent Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nuvalent Inc. is an innovative clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer patients with genetically defined diseases. Leveraging its proprietary drug discovery platform, Nuvalent aims to provide cutting-edge treatment solutions that specifically target genetic mutations driving tumor growth, ultimately enhancing patient outcomes and minimizing adverse effects. With a strong pipeline of highly selective therapies, the company is well-positioned to capitalize on the expanding precision oncology market, demonstrating a steadfast commitment to revolutionizing cancer treatment and improving patient care across the oncology sector.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?